These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 14745732)

  • 1. Reversibility of hepatitis C virus-related cirrhosis.
    Pol S; Carnot F; Nalpas B; Lagneau JL; Fontaine H; Serpaggi J; Serfaty L; Bedossa P; Bréchot C
    Hum Pathol; 2004 Jan; 35(1):107-12. PubMed ID: 14745732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis.
    Abergel A; Darcha C; Chevallier M; Ughetto S; Henquell C; Pol S; de Ledinghen V; Canva V; Bronowicki JP; Tran A; Martineau N; Lafeuille H; Dechelotte P; Bommelaer G; Bonny C;
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1219-27. PubMed ID: 15489585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.
    Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2013; 56(1):37-45. PubMed ID: 23037768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A clinical study of antiviral therapy for patients with compensated hepatitis C cirrhosis].
    Xie ZW; Li JP; Guan YJ; Zhang XY; Guo FX; Chen BB; Pan CQ
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):827-833. PubMed ID: 29325276
    [No Abstract]   [Full Text] [Related]  

  • 9. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B; Gervain J; Horváth G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():3-24. PubMed ID: 24631886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. α-fetoprotein levels after interferon therapy predict regression of liver fibrosis in patients with sustained virological response.
    Tachi Y; Hirai T; Ishizu Y; Honda T; Kuzuya T; Hayashi K; Ishigami M; Goto H
    J Gastroenterol Hepatol; 2016 May; 31(5):1001-8. PubMed ID: 27123974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment laparoscopic appearance of the liver can predict response to combination therapy with interferon alpha 2B and ribavirin in chronic hepatitis C.
    Bajaj JS; Molina E; Regev A; Schiff ER; Jeffers LJ
    Gastrointest Endosc; 2003 Sep; 58(3):380-3. PubMed ID: 14528212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NIH Consensus Statement on Management of Hepatitis C: 2002.
    NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
    Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
    Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P; Lidove O; Maisonobe T; Duhaut P; Thibault V; Ghillani P; Myers RP; Leger JM; Servan J; Piette JC
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
    Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
    Sporea I; Sirli R; Curescu M; Gheorghe L; Popescu A; Bota S; Iacob S
    J Gastrointestin Liver Dis; 2010 Sep; 19(3):261-4. PubMed ID: 20922189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.